309 related articles for article (PubMed ID: 25749417)
1. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
2. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
5. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
6. Risk of serious neutropenic events in cancer patients treated with bevacizumab: a meta-analysis.
Zhou F; Shao JH; Wu LQ; Yin XB; Yu X
Asian Pac J Cancer Prev; 2013; 14(4):2453-9. PubMed ID: 23725157
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups.
Qi WX; Fu S; Zhang Q; Guo XM
Clin Drug Investig; 2014 Oct; 34(10):681-90. PubMed ID: 25096848
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Schutz FAB; Je Y; Azzi GR; Nguyen PL; Choueiri TK
Ann Oncol; 2011 Jun; 22(6):1404-1412. PubMed ID: 21115602
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Hapani S; Sher A; Chu D; Wu S
Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX; Shen Z; Tang LN; Yao Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
BMC Med; 2014 Nov; 12():203. PubMed ID: 25369798
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
16. Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Muss HB
Breast Cancer Res Treat; 2015 Jan; 149(2):321-30. PubMed ID: 25385179
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis.
Chen XL; Lei YH; Liu CF; Yang QF; Zuo PY; Liu CY; Chen CZ; Liu YW
PLoS One; 2013; 8(6):e66721. PubMed ID: 23818962
[TBL] [Abstract][Full Text] [Related]
18. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
19. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
20. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.
Dai F; Shu L; Bian Y; Wang Z; Yang Z; Chu W; Gao S
Clin Drug Investig; 2013 Nov; 33(11):779-88. PubMed ID: 23979925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]